In a report released today, Gil Blum from Needham maintained a Buy rating on TScan Therapeutics, with a price target of $6.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Gil Blum has given his Buy rating due to a combination of factors that highlight TScan Therapeutics’ strategic focus and financial stability. The company ended the third quarter of 2025 with a substantial cash reserve of $184.5 million, which is projected to sustain its operations into the second half of 2027. This financial position provides a solid foundation for the company’s ongoing and future initiatives.
Additionally, TScan is prioritizing the development of TSC-101, particularly in the transplant setting, with pivotal study initiation expected in the second quarter of 2026. While the company has paused enrollment in the PLEXI-T study for solid malignancies, it plans to disclose safety and efficacy results from its solid tumor program in the first quarter of 2026. These strategic decisions and upcoming milestones contribute to the positive outlook reflected in the Buy rating.
Blum covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Autolus Therapeutics, and Taysha Gene Therapies. According to TipRanks, Blum has an average return of 4.7% and a 39.76% success rate on recommended stocks.
In another report released today, LifeSci Capital also reiterated a Buy rating on the stock with a $6.00 price target.